Table 2.

Base Case and Scenario Analyses Results

Strategy		Total cost per person ($)	Total QALY per person	Incremental cost per person ($)	Incremental QALY per person	Incremental cost-effectiveness ratio ($/QALY)
Base Case Scenario: 3 linkage models
Base Case Results
	No Intervention	129, 800	6.922	---	---	---
	Control Strategy	139, 900	7.299	10, 100	0.377	dominated
	Intervention	147, 200	7.627	7, 300	0.328	24, 600
Quality of Life Minimum Estimator Scenario
	No Intervention	129, 800	7.310	---	---	---
	Control Strategy	139, 900	7.602	10, 100	0.293	dominated
	Intervention	147, 200	7.852	7, 300	0.250	29,200
Early Stage Disease Treatment Restriction Scenario^a
	No Intervention	129,300	6.912	---	---	---
	Control Strategy	138, 900	7.264	9,600	0.352	dominated
	Intervention	145, 600	7.569	6, 700	0.305	24,800
Scenario Analysis: 4 linkage models
Base Case Results
	No Intervention	129, 800	6.923	---	---	---
	Control Strategy	139, 900	7.299	10, 100	0.377	dominated
	HCV Only Strategy	146,900	7.624	7, 000	0.324	24, 400
	Intervention	147,200	7.627	300	0.003	76,500
Quality of Life Minimum Estimator Scenario
	No Intervention	129, 800	7.310	---	---	---
	Control Strategy	139, 900	7.602	10, 100	0.292	dominated
	HCV Only Strategy	146,900	7.849	7, 000	0.247	31,700
	Intervention	147,200	7.852	300	0.003	88,300
Early Stage Disease Treatment Restriction Scenario^a
	No Intervention	129, 300	6.912	---	---	---
	Control Strategy	138, 800	7.264	9,500	0.352	dominated
	HCV Only Strategy	145, 300	7.565	6,500	0.302	24,500
	Intervention	145, 600	7.569	300	0.003	81,000

QALY = Quality-Adjusted Life Year

Note: all costs are in 2015 US dollars.

Early treatment restriction represents delaying access to HCV treatment medication until developing cirrhosis (F3 metavir liver staging)